CryoLife Announces Additions to Management Team
October 30 2007 - 2:00AM
PR Newswire (US)
ATLANTA, Oct. 30 /PRNewswire-FirstCall/ -- CryoLife, Inc.
(NYSE:CRY), a biomaterials, medical device and tissue processing
company, announced today that Scott B. Capps has been named vice
president, clinical research, effective October 29, 2007. Mr. Capps
has served as vice president and general manager of CryoLife
Europa, Ltd., based in the U.K., since February 2005. Mr. Capps
joined CryoLife in 1995 and has held several positions with the
Company including project director for heart valves, director of
clinical research and director of European clinical affairs. He is
a graduate of the Georgia Institute of Technology and holds a
Master's degree in bioengineering from Clemson University. In a
related move, David N. Hollinworth, Ph.D., has joined the company
as vice president and general manager of CryoLife Europa, Ltd.,
effective October 29, 2007. Previously, Dr. Hollinworth held
various management positions including chief executive officer of
Chameleon Biosurfaces, European cardiology marketing manager of
Siemens Medical and European market development manager in
cardiology at Medtronic. Dr. Hollinworth holds a Ph.D. in
biochemistry from The University of Bristol and an M.B.A. from the
London Business School. "Scott did a terrific job for CryoLife
Europa, and we are very excited about tapping into the expertise he
gained while there. His experiences with CryoLife, both in Europe
and stateside, make him well qualified to lead our clinical
operations here," said Steven G. Anderson, president and CEO of
CryoLife, Inc. "I am also very pleased to welcome Dr. Hollinworth
as general manager of CryoLife Europa. His extensive background in
the marketing of new technologies and products will be of great
assistance in the introduction of our new product pipeline in the
years ahead." About CryoLife, Inc. Founded in 1984, CryoLife, Inc.
is a leader in the processing and distribution of implantable
living human tissues for use in cardiac and vascular surgeries
throughout the United States and Canada. The Company's BioGlue(R)
Surgical Adhesive is FDA approved as an adjunct to sutures and
staples for use in adult patients in open surgical repair of large
vessels. BioGlue is also CE marked in the European Community and
approved in Canada and Australia for use in soft tissue repair. The
Company also distributes the CryoLife-O'Brien(R) stentless porcine
heart valve, which is CE marked for distribution within the
European Community. For additional information about the company,
visit CryoLife's Web site: http://www.cryolife.com/ CryoLife Media
Contacts: D. Ashley Lee Executive Vice President, Chief Operating
Officer and Chief Financial Officer CryoLife, Inc. Phone:
770-419-3355 Katie Brazel Fleishman-Hillard Phone: 404-739-0150
DATASOURCE: CryoLife, Inc. CONTACT: D. Ashley Lee, Executive Vice
President, Chief Operating Officer and Chief Financial Officer of
CryoLife, Inc., +1-770-419-3355; or Katie Brazel of
Fleishman-Hillard, +1-404-739-0150, for CryoLife, Inc. Web site:
http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From May 2024 to Jun 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2023 to Jun 2024